Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Precipio, Inc. stock (symbol: PRPO) underwent a total of 4 stock splits.
The most recent stock split occured on Sep 22, 2023.
Date | Splite | Multiple |
---|---|---|
2023-09-22 | 1:20 | 1 |
2019-04-29 | 1:15 | 1 |
2017-06-13 | 1:30 | 1 |
2014-01-28 | 1:12 | 1 |